Onset of valganciclovir resistance in two infants with congenital cytomegalovirus infection. (September 2020)

• Record Type: Journal Article
• Authors: Garofoli, Francesca; Lombardi, Giuseppina; Angelini, Micol; Campanini, Giulia; Zavattoni, Maurizio; Baldanti, Fausto
• Is Part Of: International journal of infectious diseases. Volume 98(2020)
• Page Start: 150
• Page End: 152
• Publication Date: 2020-09
• Subjects: Congenital cytomegalovirus -- Resistance -- Long-term therapy; Communicable diseases -- Periodicals; Communicable Diseases -- Periodicals; Communicable diseases; Periodicals; Electronic journals; 616.9
• DOI: 10.1016/j.ijid.2020.06.087
• Languages: English
• ISSNs: 1201-9712

Abstract

Highlights: V-GCV resistance cases, consequent to cCMV infection treatment, are being reported. Long therapeutic exposures to V-GCV are related to resistance. Strategies to monitor possible V-GCV resistance onset are required. Routine dosage/weight adjustment and monthly viral load assessment are appropriate. Therapeutic drug monitoring could be suggested to verify proper GCV blood level. Abstract: Ganciclovir and its prodrug valganciclovir are elective treatments for cCMV. Neonates with important symptoms undergo 6 months of therapy to ameliorate/prevent symptoms and late sequelae, but evidence of resistance is emerging. Over the last 5 years, we took care of 59 cCMV infants and experienced two cases of resistance among nine cCMV infants receiving long-term valganciclovir therapy. In the first case, valganciclovir therapy was prolonged beyond 6 months due to severity of symptoms, control of viral load, and absence of adverse events. Resistance was detected in the 8th month of therapy. In the second case, after a significant reduction following valganciclovir administration and no adverse events, CMV viral load suddenly increased in the 6th month of therapy due to resistance. Both events were associated with UL97 gene mutation. The cCMV infants, affected by severe symptoms, remained in a steady state during treatment, and their later neurological development was coherent with initial seriousness of diagnosis. Prolonged therapeutic exposure may therefore be a risk for resistance, suggesting that constant dosage/weight adjustments, monthly surveillance of viral load, and therapeutic drug monitoring could be proposed to monitor resistance onset and optimize the therapy regime. The risk–benefit ratio for long-term therapy, including the possibility of resistance onset, alongside SNHL and neurodevelopmental improvement, should also be evaluated.